<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182479</url>
  </required_header>
  <id_info>
    <org_study_id>215.1104</org_study_id>
    <nct_id>NCT02182479</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients</brief_title>
  <official_title>Comparison of the Safety and Efficacy of Berodual® Administered Via Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d.) With That Administered Via the MDI (50 µg Fenoterol Hydrobromide/21 µg Ipratropium Bromide, 2 Puffs q.i.d.) in Asthma Patients Over a 12-week Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to demonstrate that at least one of the two doses of Berodual® (50 µg fenoterol&#xD;
      hydrobromide/20 µg ipratropium bromide and 25 µg fenoterol hydrobromide/10 µg ipratropium&#xD;
      bromide, 1 puff q.i.d.) administered via Respimat® gives a bronchodilator response which is&#xD;
      not inferior to that obtained from one dose of Berodual® (50 µg fenoterol hydrobromide/21 µg&#xD;
      ipratropium bromide, 2 puffs q.i.d.) administered via MDI and that the safety profile is at&#xD;
      least as good in asthma patients treated for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <primary_completion_date type="Actual">June 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average FEV1 (Forced expiratory volume in one second) (AUC0-6 (Area under the curve))</measure>
    <time_frame>Pre-dose and 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on day 1, 29, 57 and 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1max</measure>
    <time_frame>Pre-dose and 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on day 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of therapeutic response</measure>
    <time_frame>Days 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of therapeutic response</measure>
    <time_frame>Days 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak FEV1</measure>
    <time_frame>Pre-dose and 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on days 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in averaged weekly morning and evening pre-dose PEFR (peak expiratory flow rate)</measure>
    <time_frame>up to day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of use of rescue medication</measure>
    <time_frame>up to day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in night-time and daytime symptom scores</measure>
    <time_frame>up to day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of adverse events</measure>
    <time_frame>up to day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in Heart rate</measure>
    <time_frame>Pre-dose and 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on days 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in Blood pressure</measure>
    <time_frame>Pre-dose and 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes post-dose on days 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes from baseline in laboratory investigations</measure>
    <time_frame>Baseline and day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of paradoxical bronchoconstriction</measure>
    <time_frame>up to day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">631</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Berodual® via Respimat®, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Berodual® via Respimat®, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Berodual® via MDI, high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo via Respimat®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo via MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® via Respimat®, high dose</intervention_name>
    <arm_group_label>Berodual® via Respimat®, high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® via Respimat®, low dose</intervention_name>
    <arm_group_label>Berodual® via Respimat®, low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® via MDI, high dose</intervention_name>
    <arm_group_label>Berodual® via MDI, high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Respimat®</intervention_name>
    <arm_group_label>Placebo via Respimat®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <arm_group_label>Placebo via MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of bronchial asthma according to the ATS (American Thoracic Society)&#xD;
&#xD;
          -  Age: 18 - 65 years&#xD;
&#xD;
          -  Screening FEV1: 40 - 80 % of predicted normal. Predicted normal values will be based&#xD;
             on the guidelines for standardised function testing of the European Community for Coal&#xD;
             and Steel&#xD;
&#xD;
          -  Airway obstruction reversibility: increase in FEV1 12% from baseline and ≥ 200 ml from&#xD;
             baseline at 30 minutes after 2 puffs of Berodual® MDI&#xD;
&#xD;
          -  Current non-smoker or ex-smoker (with a smoking history of ≤ 10 pack-years) with&#xD;
             cessation of smoking ≥ 1 year prior to the screening visit&#xD;
&#xD;
          -  Male or female patients&#xD;
&#xD;
          -  Ability to be trained in proper use of MDI and RESPIMAT® devices&#xD;
&#xD;
          -  Ability to perform technically satisfactory pulmonary function tests&#xD;
&#xD;
          -  No hospital admission for an exacerbation and stable dosage of all pulmonary&#xD;
             medication in the last four weeks (except for long acting β2 agonists)&#xD;
&#xD;
          -  Willingness and ability to sign informed consent form prior to participation in the&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with significant disease other than asthma, e.g. history of clinically&#xD;
             significant cardiovascular, renal, neurological, hepatic or endocrine dysfunction. A&#xD;
             clinically significant disease is defined as a disease which in the opinion of the&#xD;
             investigator may either put the patient at risk because of participation in the study&#xD;
             or which may influence the results of the study or the ability of the patient to&#xD;
             participate in and complete the study&#xD;
&#xD;
          -  History of myocardial infarction within the last year&#xD;
&#xD;
          -  Tuberculosis with indication for treatment&#xD;
&#xD;
          -  History of cancer within the last five years, excluding treated basal cell carcinoma&#xD;
&#xD;
          -  Patients who have undergone thoracotomy for pulmonary resection of more than one&#xD;
             bullae, or with subsequent impaired thoracic muscle performance leading to&#xD;
             unsatisfactory lung function testing&#xD;
&#xD;
          -  Current psychiatric disorders&#xD;
&#xD;
          -  History of life threatening pulmonary obstruction, cystic fibrosis or bronchiectasis&#xD;
&#xD;
          -  An upper or lower respiratory tract infection in the four weeks prior to the screening&#xD;
             visit (= Visit 1) or during the 2-week run-in period&#xD;
&#xD;
          -  Patients with clinically significant abnormal baseline haematology, blood chemistry or&#xD;
             urinalysis, if the abnormality defines a disease listed as an exclusion criterion&#xD;
&#xD;
          -  Patients with AST/ALT (aspartate amino transferase/alanine amino transferase)&#xD;
             (SGOT/SGPT (serum glutamic oxaloacetic transaminase/serum glutamic pyruvic&#xD;
             transaminase)) &gt; 200%, bilirubin &gt; 150% (except isolated bilirubin increase due to&#xD;
             Gilbert's Syndrome), or creatinine &gt; 125% of the upper limit of the normal range&#xD;
&#xD;
          -  Intolerance to aerosolised fenoterol- or ipratropium-containing products, and/or&#xD;
             hypersensitivity to any of the MDI ingredients&#xD;
&#xD;
          -  Patients using oral corticosteroid medication at unstable (i.e. less than 4 weeks on a&#xD;
             stable dose) or at a dose in excess of the equivalent of 10 mg prednisone per day or&#xD;
             20 mg every other day&#xD;
&#xD;
          -  Beta-blocker medication&#xD;
&#xD;
          -  Patients who have taken an investigational drug one month or six half-lives (whichever&#xD;
             is greater) prior to the screening visit&#xD;
&#xD;
          -  History of drug abuse and/or alcoholism&#xD;
&#xD;
          -  Pregnant or nursing women and women of childbearing potential or less than 2 years&#xD;
             postmenopausal, who are not using medically approved means of contraception (oral&#xD;
             contraceptives, intra-uterine devices or surgical Sterilisation)&#xD;
&#xD;
          -  Previous participation in this study&#xD;
&#xD;
          -  Patients who need more than 8 puffs of salbutamol (100 µg per puff) rescue medication&#xD;
             on 3 or more consecutive days during the run-in period&#xD;
&#xD;
          -  Severe bronchial asthma with frequent nocturnal asthma attacks or acute exacerbations&#xD;
             induced by recurrent bronchial infections several times per year&#xD;
&#xD;
          -  Patients with known hypersensitivity to anticholinergic drugs&#xD;
&#xD;
          -  Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction&#xD;
&#xD;
          -  Patients with known narrow-angle glaucoma&#xD;
&#xD;
          -  Patients who did not fill in at least 80% of the diary in the run-in period for both,&#xD;
             medication taken and peak expiratory flow rate (PEFR) measurements are considered not&#xD;
             compliant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/215/215.1104_U01-1083.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenoterol</mesh_term>
    <mesh_term>Fenoterol, ipratropium drug combination</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

